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MaThe goal of this systematic analysis is to provide a comprehensive review of the current cardiac magnetic resonance
data on microvascular obstruction (MVO) and intramyocardial hemorrhage (IMH). Data related to the association of
MVO and IMH in patients with acute myocardial infarction (MI) with left ventricular (LV) function, volumes, adverse
LV remodeling, and major adverse cardiac events (MACE) were critically analyzed. MVO is associated with a lower
ejection fraction, increased ventricular volumes and infarct size, and a greater risk of MACE. Late MVO is shown to be
a stronger prognostic marker for MACE and cardiac death, recurrent MI, congestive heart failure/heart failure hos-
pitalization, and follow-up LV end-systolic volumes than early MVO. IMH is associated with LV remodeling and MACE
on pooled analysis, but because of limited data and heterogeneity in study methodology, the effects of IMH on
remodeling require further investigation. (J Am Coll Cardiol Img 2014;7:940–52) © 2014 by the American College of
Cardiology Foundation.SEE PAGE 953I n the setting of an acute myocardial infarction(MI), persistence of coronary artery occlusionfor >40 min can lead to irreversible myocardial
damage that spreads as a “wave front phenomenon”
progressing from endocardium to epicardium (1,2).
Although timely reperfusion is presently the best
mechanism to salvage ischemic myocardium and
limit myocardial necrosis, revascularization also can
have detrimental effects by triggering ischemic
reperfusion injury that results in microvascular
damage and further myocyte necrosis (3). Ischemic
reperfusion injury can account for up to one-half of
the size of the ﬁnal MI (4). Depending on the
severity of the ischemic injury, microvascular injury
can lead to: 1) microvascular obstruction (MVO)
only; and 2) MVO with intramyocardial hemorrhage
(IMH) (4). The National Heart, Lung, and Blood
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AB BR E V I A T I O N S
AND ACRONYM S
CHF = congestive heart failure
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
EF = ejection fraction
EMVO = early microvascular
obstruction
FPP = ﬁrst-pass perfusion
IMH = intramyocardial
hemorrhage
IS = infarct size
LMVO = late microvascular
obstruction
LV = left ventricular
LVEF = left ventricular
ejection fraction
MACE = major adverse cardiac
events





STEMI = ST-segment elevation
myocardial infarction
STIR = short-tau inversion
recovery
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941MICROVASCULAR OBSTRUCTION. MVO or “no
reﬂow” refers to the small vessel changes that prevent
adequate tissue perfusion despite revascularization
and an open epicardial coronary artery (2). MVO is
thought to be caused by an abrupt release of
cytotoxic factors (7) that promote vasoconstriction,
myocardial cellular edema (2,8), capillary endothelial
cells swelling, and distal microembolization of
atherosclerotic debris leading to plugging of vascular
lumen with neutrophils, red blood cells, and platelets.
MVO begins in the infarcted core and can increase
in size for up to 48 h (9). MVO is reported to be
present in up to 84% of the patients after ST-segment
elevation myocardial infarction (STEMI) (10–12). The
diagnosis of MVO can be made using angiography
(13,14), echocardiography (15), nuclear scintigraphy
(16), myocardial contrast echocardiography (17), or
CMR. On angiography, microvascular blood ﬂow
is assessed using Thrombolysis In Myocardial
Infarction ﬂow grades, myocardial blush grade, and/
or corrected Thrombolysis In Myocardial Infarction
frame count. The rate of myocardial uptake of
microbubbles using contrast echocardiography has
been used to assess MVO; however, this technique is
limited by challenges of adequate acoustic windows,
injection of microbubble contrast, and operator
dependency (17). There are limited data using single
photon emission computed tomography, and this
has been used only in research applications (16). Of
the available modalities, CMR provides the most
comprehensive assessment of MVO.
MVO is detected on gadolinium-enhanced CMR as
delayed or absent wash-in of contrast agent into the
infarct zone. MVO as assessed by CMR is deﬁned as
“early” or “late” in reference to the timing of imaging
relative to gadolinium administration (Figure 1). Early
microvascular obstruction (EMVO) is identiﬁed by a
prolonged perfusion defect on resting ﬁrst-pass
perfusion (FPP) imaging (18) or as a hypointense
region in the core of the infarct on T1-weighted
images obtained 2 to 5 min after contrast
administration (19). Although FPP images have
lower signal-to-noise ratio, spatial coverage, and
ventricular coverage, a study comparing this
technique with early T1-W imaging demonstrated
concordance in 92% (20).
Depending on the severity of MVO, the absence
of wash-in of gadolinium may persist for >10 min (21),
resulting in a region of persistent hypoenhancement
within the core of the infarct on conventional late
gadolinium enhancement images, referred to as
“late MVO” (LMVO). Late gadolinium enhancement
imaging used for LMVO assessment has high spatial
and contrast resolution (22) and enables full coverageof the LV myocardium. Because the wash-in
of gadolinium into the infarct core is a
dynamic process (23,24), it is presently
unknown whether the rate of ﬁll-in of the
MVO area has prognostic importance
and whether EMVO or LMVO is a better
predictor of LV remodeling or MACE.
INTRAMYOCARDIAL HEMORRHAGE. IMH is
considered a severe form of MVO and
follows MVO development in the core of the
infarct (25–27) with a tendency to expand for
several hours after percutaneous coronary
intervention (28,29). The cause includes
vascular endothelial damage and accumula-
tion of red blood cells in the myocardial
extracellular space (30–34). It has been
debated whether IMH is the cause or result
of severe ischemic reperfusion injury (35).
A high correlation between infarct size
(IS) and IMH has been identiﬁed on
histopathologic studies (r ¼ 0.90); however,
no correlation with the magnitude of early
ﬂow after revascularization (32,36,37) has
been seen. Multiple factors contribute to
the presence and severity of IMH, including
the amount of collateral ﬂow (25,38),
ischemic preconditioning, extent of necrosis
(25,33), distal coronary microembolization,
and differences in individual risk factors, such as
diabetes or smoking. IMH can be assessed with CMR
using T2- or T2*-weighted imaging or parameter
mapping sequences (Figure 2).
Most studies have used T2-weighted short-tau
inversion recovery (STIR) or T2*-weighted gradient
echo pulse sequences to assess for IMH. IMHappears as
a hypointense region within the infarct
on T2-weighted sequences because the hemoglobin
breakdown products shorten the myocardial
T2-relaxation time. Because the paramagnetic effects
of hemoglobin breakdown products more strongly
affect T2* relaxation, T2*-weighted imaging is thought
to be more sensitive for the detection of IMH (39,40).
However, T2*-weighted images have lower signal-to-
noise compared with T2-weighted images and are
more sensitive to off-resonance artifacts. T2* values
are lowest acutely in the IMH core, but gradually
normalize to that of the rest of the infarct at 4 weeks
because of extensive collagen deposition and absence
of iron with resolution of MVO and IMH (41). IMH
detected by both T2 (41,42) and T2* images has been
correlated with the presence of hemorrhage on
histopathologic analysis (kappa 0.96, p < 0.01)
(43–45) (Figures 3 and 4). A recent study (46) in
FIGURE 1 Cardiac Magnetic Resonance (CMR) Images From a 46-Year-Old Man With Diabetes and Chest Pain
(A) First-pass perfusion (FPP) image shows a region of hypoperfusion in the anteroseptum (early microvascular obstruction [EMVO]). (B) Phase-
sensitive inversion recovery (PSIR) sequence reveals presence of myocardial infarction (MI) with large area of late microvascular obstruction
(LMVO). These ﬁndings were consistent with an acute MI in a diagonal branch that was originally missed on (C) cardiac catheterization
(arrow shows proximal diagonal branch obstruction).
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94214 patients with STEMI and 20 canines with acute
reperfused MI suggests that T2* may be more suitable
than T2 imaging techniques for assessing myocardial
hemorrhage. The T2* decreased on average 54% in
hemorrhagic infarctions and was 6% higher inFIGURE 2 Example Images From a Study of Reperfused Acute MI in
The images from the ﬁrst animal (top) show (A) decreased perfusion in
intramyocardial hemorrhage on T2* mapping, and (C) a corresponding h
imaging, consistent with microvascular obstruction (MVO) with IMH. Im
reduced perfusion on FPP imaging, (E) T2* maps do not demonstrate an
absence of MVO or IMH.nonhemorrhagic infarctions compared with remote
myocardium. On the contrary, the T2 was increased
by 17% in hemorrhagic infarcts and by 38% in
nonhemorrhagic infarcts in the canine model,
reﬂecting the competing effects of hemorrhage,a Porcine Model
the mid-anteroseptal wall on FPP imaging, (B) an area of
ypointense area on phase-sensitive late gadolinium enhancement
ages from the second animal (bottom) (D) demonstrate an area of
y IMH, and (F) late gadolinium enhancement images demonstrate the
FIGURE 3 Transmural Anteroseptal and Lateral Hemorrhagic MI in a Patient Who Died of Cardiogenic Shock After Acute MI and
Who Had Undergone Coronary Recanalization
Gross anatomic image obtained at the time of autopsy (A), histology image after staining with Heidenhain trichrome stain (B), and ex vivo T2
CMR image from the short-axis slice (C) show the changes. Adapted with permission from Basso et al. (43).
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943which tends to shorten T2, with that of edema, which
increases T2 (46). More studies performing direct
comparison of T2 and T2* techniques will provide a
promising approach to differentiate MVO with and
without IMH. In some cases, it is difﬁcult to
adequately differentiate MVO from IMH because both
may appear as a hypointense region within the
infarct (44,47,48). Furthermore, MVO without
hemorrhage can result in hypoenhanced regions seen
on T2-weighted sequences because of low proton
density in the infarct core (48). Thus, care must be
used when distinguishing between MVO and IMH on
T2-weighted images.
Pre-contrast T1-weighted inversion recovery im-
ages have demonstrated promise for detecting IMH in
a porcine model of MI (49). As hemorrhage shortens
T1, regions of hemorrhage appear bright on this
sequence. In this study, the diagnostic sensitivity
of the T1-weighted image was higher than thatFIGURE 4 Images From a Mongrel Dog in Which MI Was Experimen
CMR was performed day 3 after reperfusion in which T2*-weighted grad
triphenyl tetrazolium chloride staining were performed to assess for MVO
Kumar et al. (45). CMR ¼ cardiac magnetic resonance; LGE ¼ late gadofor T2*-weighted or T2-weighted imaging. This
technique requires further clinical validation.
METHODS
We conducted a systematic review by searching
PubMed for all published studies evaluating the rela-
tionship of MVO or IMH with LV remodeling and
MACE through January 2014. The QUORUM diagram
for our search methodology is presented in Figure 5.
MACE are deﬁned in studies as a composite of
various secondary outcomes, including cardiac
death, death, recurrent MI, congestive heart failure
(CHF), CHF-related hospitalizations, unstable angina
(50), embolic stroke (51), and atrial ﬁbrillation,
whichever occurred ﬁrst. Variation in data
presentation was identiﬁed.
We assessed the association of presence of EMVO
or LMVO on clinical outcomes of MACE, cardiactally Induced
ient echo imaging was performed. Ex vivo, thioﬂavin S imaging, and
, hemorrhage, and myocardial necrosis. Adapted with permission from
linium enhancement; TTC ¼ triphenyl tetrazolium chloride.
1) MVO and volumes, 
2) MVO and salvage,
3) MVO and ejection fraction,
4) MVO and heart failure, 
5) MVO and left ventricular
    remodeling,
6) MVO and magnetic resonance
    imaging, 
7) MVO and prognosis.
472 Manuscripts
121 Manuscripts
(After review of abstracts and removal
of duplicates and studies not looking
at the direct association)
33 Manuscripts
(After review of full text articles
and their bibliographies)
MVO and LV Remodeling
(LVESD, LVEDD, IS, LVEF)
Search Terms
1) MVO and magnetic resonance
    imaging, 
2) MVO and prognosis, 
3) MVO and mortality, 
4) MVO and injury, 
5) MVO and MI, 
6) MVO and sudden cardiac death, 
7) MVO and scar and 
8) MVO and late gadolinium
    enhancement (LGE).
703 Manuscripts
26 Manuscripts
(After review of abstracts and removal
of duplicates and studies not looking
at the direct association)
18 Manuscripts
(After review of full text articles
and their bibliographies)
MVO and Major Adverse
Cardiovascular Events (MACE)
Search Terms
1) IMH and magnetic resonance
     imaging, 
2) IMH and left ventricular
     remodeling.
43 Manuscripts
20 Manuscripts
(After review of abstracts and removal
of duplicates and studies not looking
at the direct association)
9 Manuscripts
(After review of full text articles
and their bibliographies)
IMH and LV Remodeling
(LVESD, LVEDD, IS, LVEF)
and MACE
Search Terms
FIGURE 5 QUORUM Diagram Showing Details of the PubMed Search Conducted Through January 2014 on 3 Topics
1) MVO and left ventricular (LV) remodeling; 2) MVO and major adverse cardiac events (MACE); and 3) IMH and LV remodeling. IMH ¼
intramyocardial hemorrhage; IS ¼ infarct size; LGE ¼ late gadolinium enhancement; LV ¼ left ventricular; LVEDD ¼ left ventricular
end-diastolic diameter; LVEF ¼ left ventricular ejection fraction; LVESD ¼ left ventricular end-systolic diameter; MACE ¼major adverse cardiac
events; MVO ¼ microvascular obstruction.
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944death, CHF-related hospitalization, and recurrent MI.
Studies were assessed by 2 reviewers (Y.H. and A.W.)
to determine whether the studies met the speciﬁed
inclusion criteria. A random effects meta-analysis
using Mantel-Haenszel weighting was performed to
calculate pooled odds ratios and 95% conﬁdence
intervals (CIs) for these outcomes. In studies that
performed both EMVO and LMVO in the same sub-
jects, a comparison of the difference in odds ratios for
each endpoint between EMVO and LMVO was per-
formed using an inverse-variance weighted meta-
analysis with a variance estimate that took into
account intra-study correlation between EMVO and
LMVO (52).
We evaluated the association between EMVO and
LMVO and LV function, volumes, and IS at baseline
and on follow-up imaging. Because the majority of
studies presented indexed LV volumes, indexed vol-
umes were included in the analysis of LV volumes.
Studies reporting only nonindexed volumes were
excluded. Studies reporting data as median and
interquartile range were excluded from the analysis,
because the mean and variance could not bedetermined without using a normality assumption,
which could not be veriﬁed without patient-level
data. Inverse variance-weighted, random-effects
meta-analysis of the mean differences in indexed LV
volumes, ejection fraction (EF), and IS between pa-
tients with or without MVO on their initial imaging
study after MI was performed for studies assessing
EMVO or LMVO. To assess LV remodeling as a func-
tion of the presence or absence of MVO on the initial
imaging study, a similar meta-analysis of the mean
differences in volume EF and IS on follow-up studies
obtained more than 4 months after the initial MI was
performed.
Similar analysis was performed for IMH to assess
the relationship between IMH and MACE and LV vol-
umes and function. A random-effects meta-analysis
with Mantel-Haenszel weights was performed assess-
ing the hazard ratio for endpoints of cardiac death,
recurrent MI, and CHF/CHF hospitalization.
Meta-analysis was performed using Review
Manager (RevMan) 5 version 5.1.7 freeware package
(The Nordic Cochrane Centre, The Cochrane Collab-
oration, 2008, Copenhagen, Denmark). Heterogeneity
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945was assessed with the I2 statistic, and funnel plots
were performed to assess for publication bias. No
formal meta-regression was performed to explore
heterogeneity because of the variation in reporting
of important covariates and the scope of this review.TABLE 1 Mean Difference (IV and 95% CI) From Studies of Impact of EMVO and LMVO
on Baseline and Follow-Up (4 Months to 1 Year) LVEF, LVEDV, LVESV, and IS
Mean Difference (IV, Random, 95% CI)
From Pooled Analysis
(EMVO)




EF (%) 5.21 (7.13 to 3.30)* 5.82 (8.21 to 3.43)*
IS (% LV) 10.71 (8.49 to 12.92)* 13.01 (9.95 to 16.07)*
LVEDVi (ml/m2) 6.73 (3.32 to 10.14)† 5.26 (1.08 to 11.60)‡
LVESVi (ml/m2) 6.73 (6.10 to 7.37)* 9.06 (1.76 to 16.3)§
Follow-Up (4 Months to 1 Yr)
EF (%) 7.44 (9.07 to 5.80)* 7.76 (9.63 to 5.90)*
IS (% LV) 6.85 (3.65 to 10.06)† 6.91 (0.35 to 13.47)k
LVEDVi (ml/m2) 16.44 (13.10 to 19.77)* 17.14 (7.20 to 27.08)¶
LVESVi (ml/m2) 13.08 (10.26 to 15.90)* 19.59 (6.76 to 32.42)#
*p < 0.00001. †p < 0.0001. ‡p ¼ 0.10. §p ¼ 0.02. kp ¼ 0.04. ¶p ¼ 0.0007. #p ¼ 0.003.
CI ¼ conﬁdence interval; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; EMVO ¼ early microvascular
obstruction; ESV ¼ end-systolic volume; IS ¼ infarct size; IV ¼ inverse variance; LMVO ¼ late microvascular
obstruction; LV ¼ left ventricular; LVEDVi¼ left ventricular end-diastolic volume index; LVESVi ¼ left ventricular
end-systolic volume index; MVO ¼ microvascular obstruction.RESULTS
The pooled mean prevalence of EMVO, LMVO, and
IMH in the studies reviewed was 65% (95% CI:
63% to 66%), 54% (95% CI: 52% to 56%), and 35%
(95% CI: 31% to 38%), respectively (Online Table 1).
Some of the variability in the prevalence of MVO
between studies may be due to differences in
study populations, contrast doses, pulse sequences,
or timing of imaging post-contrast. LVEF, IS, and
LV volumes were assessed on the baseline CMR
in 12 of the 33 studies; however, only 7 studies
analyzed LV functional information at 4 months
to 1 year of follow-up. All the studies included
patients presenting with acute MI who underwent
thrombolysis or percutaneous coronary intervention
between 12 and 72 h after symptom onset. One
study exclusively included patients with non-
STEMI (53).
EFFECT OF EMVO ON LV REMODELING AND
MACE. Our review identiﬁed 10 studies (n ¼ 698)
examining the direct impact of EMVO on LV func-
tion, volumes, and remodeling, and 5 studies (791
patients) evaluating its impact on MACE. EMVO was
assessed on 1.5-T CMR scanners in 9 of 10 studies.
EMVO was assessed 24 h to 1 week after MI using the
FPP technique in 6 studies and early post–gadolin-
ium enhancement T1-weighted imaging in 5 studies
(19,20,24,54–56). The study by Ørn et al. (55) is
unique because it assessed the presence of EMVO
at multiple time points after MI, but the results
were similar to those of the companion studies.
The majority of the studies identiﬁed EMVO to be
independently associated with LV remodeling and
MACE (12,19,20,24,25,50,53,55–62). The pooled anal-
ysis is presented in Table 1, Figure 6, and Online
Table 4. On review of studies that assessed LV
remodeling both immediately after MI and at
follow-up (20,24,50,55), there was a greater
difference in EF and in particular indexed LV
volumes at follow-up compared with baseline
indicating differences in remodeling between cases
with and without EMVO.
The study of 100 patients with acute MI by Weir
et al. (12) noted that EMVO was associated with
signiﬁcantly more shrinkage of IS (delta IS) at
follow-up. In our review of 3 studies inclusive of106 patients (20,24,56) with both baseline and
follow-up IS, a similar trend was identiﬁed. Infarct
extent and infarct transmurality when studied along
with IS were noted to be increased in the presence
of EMVO (12,20,58).
Figure 6 shows the impact of EMVO on MACE,
cardiac mortality, recurrent MI, and CHF/CHF
hospitalization. Although there was a trend
toward increased cardiac mortality, MI, and CHF
hospitalization, the pooled odds ratios were not
statistically signiﬁcant.
Because studies used different methods for quan-
tifying the size of EMVO, the effects due to the size of
the region of MVO could not be assessed. In a study
by de Waha et al. (63) in 438 patients, the extents of
EMVO (hazard ratio: 1.03; 95% CI: 1.02 to 1.05) and
EMVO/IS (hazard ratio: 2.22; 95% CI: 1.60 to 3.08)
were identiﬁed as independent predictors of MACE
(62). Bruder et al. (64) identiﬁed a cutoff EMVO
value of >0.5 (% of LV mass) to predict MACE (odds
ratio: 3.9; 95% CI: 1.1 to 13.9). A trend toward
increased MACE in the presence of EMVO with
increasing IS (% LV) from 18% to 30% to >30% was
recognized by Wu et al. (50).
EFFECT OF LMVO ON LV REMODELING AND
MACE. We identiﬁed 9 studies (n ¼ 631)
(12,19,24,53,65–68) looking at the direct impact of
LMVO on LV remodeling and 7 studies (n ¼ 2,132)
(53,56,57,66,69–71) evaluating its impact on MACE
(Online Tables 5A to 5D). The majority of these
studies demonstrate an effect of LMVO on both LV
remodeling and MACE in multivariate analysis
                Early MVO Present        Early MVO Absent                              Odds Ratio
Study or Subgroup Events Total Events Total  Weight     M-H, Random, 95% CI
Odds Ratio
M-H, Random, 95% CI
Cochet (early), 2010 3 28 3 33 18.1% 1.20 [0.22, 6.48]
Cochet (early), 2009 14 127 4 57 38.3% 1.64 [0.52, 5.23]
Devaha (early), 2010 17 332 2 90 23.3% 2.37 [0.54, 10.47]
Klug (early), 2012 9 74 2 33 20.3% 2.15 [0.44, 10.53]
Total (95% CI)  561  213 100.0% 1.79 [0.87, 3.66]
Total Events 43  11
Heterogeneity: Tau2 = 0.00;   Chi2 = 0.43, df = 3 (P = 0.93);   I2 = 0%
Test for Overall Effect: Z = 1.58 (P = 0.11)
C
0.01 0.1 10 1001
Favors [Early MVO] Favors [No Early MVO]
Cochet (early), 2010 11 28 4 33 11.4% 4.69 [1.29, 17.07]
Cochet (early), 2009 38 127 6 57 22.2% 3.63 [1.44, 9.17]
Devaha (early), 2010 60 332 9 90 34.6% 1.99 [0.94, 4.17]
Klug (early), 2012 49 74 14 33 27.0% 2.66 [1.15, 6.17]
Wu (early), 1988 5 11 3 6 4.8% 0.83 [0.11, 6.11]
Total (95% CI)  572  219 100.0% 2.60 [1.68, 4.02]
Total Events 163  36
Heterogeneity: Tau2 = 0.00;   Chi2 = 3.06, df = 4 (P = 0.55);   I2 = 0%
Test for Overall Effect: Z = 4.28 (P < 0.0001)
A
0.01 0.1 10 1001
Favors [Early MVO] Favors [No Early MVO]
Cochet (early), 2010 2 28 0 33 14.8% 6.32 [0.29, 137.37]
Cochet (early), 2009 8 127 0 57 16.6% 8.18 [0.46, 144.19]
Devaha (early), 2010 20 332 5 90 52.1% 1.09 [0.40, 2.99]
Klug (early), 2012 9 74 0 33 16.5% 9.72 [0.55, 172.10]
Total (95% CI)  561  213 100.0% 2.84 [0.75, 10.67]
Total Events 39  5
Heterogeneity: Tau2 = 0.61;   Chi2 = 4.35, df = 3 (P = 0.23);   I2 = 31%
Test for Overall Effect: Z = 1.54 (P = 0.12)
D
Favors [Early MVO] Favors [No Early MVO]
0.01 0.1 10 1001
Early MVO present Early MVO absent
Cochet (early), 2010 4 28 0 33 23.4% 12.31 [0.63, 239.35]
Cochet (early), 2009 4 127 1 57 42.0% 1.82 [0.20, 16.67]
Klug, 2012 2 74 1 33 34.7% 0.89 [0.08, 10.16]
Total (95% CI)  229  123 100.0% 2.22 [0.53, 9.31]
Total Events 10  2
Heterogeneity: Tau2 = 0.00;   Chi2 = 1.94, df = 2 (P = 0.38);   I2 = 0%
Test for Overall Effect: Z = 1.09 (P = 0.28)
B
0.01 0.1 10 1001
FIGURE 6 Pooled Odds Ratios for the Association of EMVO and Adverse Cardiac Outcomes
(A) MACE, (B) cardiac death, (C) recurrent MI, and (D) congestive heart failure (CHF) or CHF-related hospitalizations. CI ¼ conﬁdence interval;
MVO ¼ microvascular obstruction.
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946(Table 1, Figure 7). The presence of LMVO predicted a
greater reduction in LVEF at both baseline and
follow-up. The point estimates for LV volume were
greater at follow-up, which would be consistent
with increased LV remodeling in the presence of
LMVO (Table 1).
LMVO has been independently associated with
IS and reduction in IS at follow-up (60,65,66). In mul-
tiple studies there was a high correlation between
LMVO and IS (r ¼ 0.75 to 0.77) (65,66). However, in a
study by Ørn et al. (55), when the presence of LMVO at
2 days versus 1 week after MI was compared, only its
presence at 2 days predicted IS at 1-year follow-up.
Ørn et al. (55) did not identify a correlation between
size of LMVO and IS, but Cochet et al. (56) detected a
signiﬁcant correlation between them (r ¼ 0.65, p <
0.0001). Some studies recorded LMVO as present
exclusively in the setting of transmural necrosis;
thus, on multivariate analysis the predictive power
of LMVO for LV remodeling was lower (72,73). Somestudies have seen an independent predictive utility
of presence and absence of MVO for LV end-diastolic
volume (74,75) and LVEF beyond that of IS (76). Most
studies (65,74,75,77–79) did not ﬁnd an additional
utility of assessing extent of LMVO to predict LV
volumes or LVEF. In our meta-analysis, the presence
of LMVO was signiﬁcantly associated with cardiac
death, recurrent MI, and CHF/CHF hospitalization
(Figure 7). In studies that performed multivariate
analysis, 4 (53,56,67) demonstrated an independent
impact of LMVO on MACE, whereas 3 (69–71) did not.
A direct comparison of the studies in regard to
LMVO size could not be performed because of varia-
tion in methods used to quantify the size of the LMVO
(i.e., % LV mass to LV segments with LMVO [score]
and MVO/IS ratio) as with EMVO. However, apart
from 4 studies (69–71,80,81), most have demon-
strated increasing LMVO size to correlate with MACE
(51,57,66,78,82–84) on multivariate analysis. A study
by Jensen et al. (82) suggested a cutoff of LMVO
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Test for Overall Effect: Z = 3.30 (P = 0.0010)
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FIGURE 7 Pooled Odds Ratios for the Association of LMVO and Adverse Cardiac Outcomes
(A) MACE, (B) cardiac death, (C) recurrent MI, and (D) CHF or CHF-related hospitalizations. Abbreviations as in Figure 6.
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947>3.9% of LV volume to predict MACE. Compared with
the other measurements of size, the MVO/IS ratio was
noted to have the strongest impact on MACE in a
study by de Waha et al. (63). Of note, LMVO size
emerged to be independently associated with MACE
and IS in most of the studies. In the study by
Hadamitzky et al. (84), in which multivariate
analysis included GRACE score, IS by both CMR and
single photon emission computed tomography and
LMVO size, only GRACE score and LMVO size were
independent predictors of MACE. Furthermore,
LMVO allowed separation between a high-risk group
(event rate 14%, 35% of patients) and a relatively
low-risk group (event rate 5.5%, 65% of patients).
COMPARISON OF EMVO VERSUS LMVO. We identi-
ﬁed 13 studies that assessed both EMVO and LMVO.
Some compared the predictive value of EMVO versus
LMVO for LV remodeling and MACE (53,55–57). A
decrease inMVO from 70% to 62% to 59% from early, to
intermediate, to late imaging has been observed in a
study by Nijveldt et al. (24). A shrinkage in absoluteMVO size, MVO:IS, and MVO transmurality between
early and late imaging also is seen and is thought to
be related to diffusion and collateral blood ﬂow (69).
Thus, EMVO is generally considered more sensitive
(60,61), whereas LMVO is more speciﬁc for
diagnosing microvascular damage (57,85). A high
correlation is noted between EMVO and LMVO with
correlation coefﬁcients in the range of 0.52 to 0.78
(56,73).
In our meta-analysis of the data from 3 studies
directly comparing EMVO and LMVO in the same
patients, LMVO had a statistically higher odds
ratios for predicting MACE (delta odds ratio: 2.56,
p < 0.001), CHF death (delta odds ratio: 2.19,
p ¼ 0.035), and recurrent MI (delta odds ratio: 2.27,
p ¼ 0.009), with a trend toward a statistically higher
estimate of cardiac death (delta odds ratio: 2.07, p ¼
0.10), assuming a correlation coefﬁcient of 0.7
between EMVO and LMVO.
Although various studies have identiﬁed both
EMVO and LMVO (56) or EMVO only (53) to be
TABLE 2 Mean Diffe
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948independently associated with MACE and LV
remodeling, the preponderance of data favors LMVO
to have the strongest relationship (57,76). In a study
by Cochet et al. (56), LMVO had a greater predictive
value for MACE (odds ratio for EMVO: 2.5; 95% CI: 1.0
to 6.2; p ¼ 0.045 vs. odds ratio for LMVO: 8.7; 95% CI:
3.6 to 21.1; p < 0.001). The comparative sensitivity,
speciﬁcity, and accuracy of EMVO versus LMVO
for the prediction of MACE were 86%, 36%, and
48% versus 84%, 65%, and 70%, respectively, in this
study.
EFFECT OF IMH ON LV REMODELING AND MACE. We
identiﬁed 9 studies (1,106 patients) that examined the
relationship between IMH and LV remodeling. The
pooled mean differences in indexed volumes, IS, and
EF between subjects with and without IMH are
presented in Table 2 and demonstrate that IMH is
associated with larger volumes, reduced EF, and
increased IS.
There was variability in the imaging techniques
used to assess IMH, and most studies have used T2-
weighted STIR imaging, rather than T2* pulse se-
quences. Only 1 study (54) used both T2 and T2* to
assess IMH, which was deﬁned as present only when
both T2 and T2* were positive. Two other studies
(27,86) used T2* only. IMH was seen predominantly
in anterior infarcts (27) and in infarcts involving
>80% of LV thickness (86). O’Regan et al. (86)
showed signiﬁcantly reduced LVEF and increased LV
volumes in patients with IMH on univariate analysis
and a strong collinearity of IMH and MVO, whereas
Ochiai et al. (27) detected no improvement in 1-
month follow-up EF (LVEF 47  9% vs. 51  10%) and
increased IS at baseline in the presence of IMH;
however, multivariate adjusted analysis was not
performed. Mather et al. (54) found an independent
correlation of IMH with LV remodeling and a
signiﬁcant improvement of diagnostic area under the
curve (from 0.699 to 0.826) by adding IMH to arence (IV and 95% CI) From Studies Assessing the Impact
EF, LVEDV, LVESV, and IS
Difference (IV, Random, 95% CI)
From Pooled Analysis
(Baseline)
Mean Difference (IV, Random, 95% CI)
From Pooled Analysis
(11 Days to 6 Months Follow-Up)
8.81 (11.13 to 6.49)* 10.86 (13.08 to 8.64)*
14.96 (11.54 to 18.37)* 11.55 (8.25 to 14.85)*
13.24 (9.32 to 17.16)* 17.44 (10.91 to 23.97)*
14.62 (11.80 to 17.43)* 17.33 (13.67 to 20.99)*
emorrhage; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular
left ventricular end-systolic volume; other abbreviations as in Table 1.multivariate model including LVEF and IS. Decreased
EF acutely and dilated LV volumes without a
signiﬁcant recovery of EF and increased LV end-
diastolic volume were seen at 3 months follow-up.
The remainder of the studies (75,81,87–89) used T2
STIR. IMH was more prevalent in patients under-
going rescue percutaneous coronary intervention
(23% vs. 7%; p < 0.0001) compared with primary per-
cutaneous coronary intervention (81). These studies
identiﬁed higher IS in the presence of combined
MVO and IMH versus MVO only, with a high
correlation between IS and IMH (r ¼ 0.53, p < 0.001)
(87). One study identiﬁed IMH on multiple regression
analysis (inclusive of IS, MVO, infarct location, and
transmurality and time to percutaneous coronary
intervention) to be strongly associated with adverse
LV remodeling (87) at 4 months (R2 ¼ 0.17, F-value:
20.19, p < 0.001). This study also showed that for
all IS quartiles, IMH was associated with larger LV
end-systolic volume. However, Husser et al. (81)
showed that although IMH was univariate predictor
of larger LV end-systolic volume on follow-up (odds
ratio: 1.54; 95% CI: 1.15 to 2.07; p ¼ 0.004) (81), it did
not improve the area under the curve for predicting
LV end-systolic volume when late gadolinium
enhancement and LVEF data were incorporated
into the model (OR: 0.914; 95% CI: 0.875 to 0.952 vs.
OR: 0.913; 95% CI: 0.875 to 0.952; p ¼ 0.9) (81).
Likewise, IMH was not a predictor of baseline or
follow-up LVEF in multivariate analysis in other
studies (75,88). Thus, it is not entirely clear whether
IMH will have signiﬁcant incremental utility for
predicting IS, ventricular volumes, and functions in
models that include other parameters of the infarct
or LV structural/functional parameters. Without a
larger head-to-head study using both T2-W and
T2* techniques, it is difﬁcult to determine which
technique has superior performance for detecting IMH.
Three studies, using T2 STIR (81,89,90), including a
total of 991 patients with a follow-up of 6 months to
3 years, examined the impact of IMH on adverse
cardiovascular outcomes. The pooled univariate
hazard ratio for of IMH for predicting MACE was 3.88
(95% CI: 2.11 to 7.13). There are mixed results for the
predictive utility of IMH in the presence of other
infarct characteristics. One study demonstrated a
trend toward more MACE in the presence of IMH with
MVO compared with MVOwithout IMH (p¼ 0.09) (90).
In the study by Eitel et al. (89), inclusion of IMH in the
risk model (which included age, infarct location,
time to treatment, LV function, and IS) increased the
C statistic from 0.76 to 0.80 (p ¼ 0.046). However,
this study did not include MVO as a covariate. In
the study by Husser et al. (81), although IMH
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949independently predicted MACE, the addition of
IMH to a model, which included late gadolinium
enhancement and cine-functional parameters, did
not improve the area under the curve for predicting
MACE. Thus, although IMH may independently
predict MACE, its incremental value over other CMR
parameters requires further clariﬁcation.
ASSOCIATION BETWEEN IMH AND MVO. In most
studies, IMH is identiﬁed only in the presence of
MVO. The correlation of IMH has been reported to be
0.30 for EMVO and between 0.89 and 0.93 for LMVO
(86,88). There are 2 theories about the association
of MVO with IMH: 1) MVO leads to endothelial
damage with subsequent leakage of red blood cells
into the interstitial space, leading to IMH; and 2) IMH
occurs as part of ischemia–reperfusion injury and
hemorrhage, which in turn leads to greater myocar-
dial swelling and compression of the microvascula-
ture, thus worsening MVO (75,79,88). The study by
Eitel et al. (89) that compared the graded impact of
no MVO, MVO only, and MVO with IMH on LV
remodeling or MACE detected a strong incremental
association. Thus, there is likely a spectrum between
MVO and MVO with IMH, with the presence of IMH
suggesting greater cellular damage resulting in
greater adverse remodeling and poorer outcomes.
STUDY LIMITATIONS. A principal limitation of the
present analysis is that most studies of MVO and IMH
are single center with small patient populations. In
addition, variable imaging techniques and timing of
imaging after MI have been used, leading to signiﬁ-
cant heterogeneity of results in the literature.
MVO and IMH are dynamic processes after MI.
Differential timing of assessment may lead to over- or
underdiagnosis. The populations studied may suffer
from selection bias because they may represent only
the patients stable enough to undergo CMR assess-
ment. Further bias may be introduced by the exclu-
sion of patients with prior MI, severe heart failure, or
cardiac arrhythmias. The estimates of effect sizespresented in this review examine only MVO and IMH
as univariate factors without correction for other
important covariates. However, the variation in
techniques used and the heterogeneity in reporting of
the data for these covariates limit the potential of
meta-regression to determine the true prognostic
utility of IMH and MVO in the presence of other fac-
tors, such as LV function and IS, which have been
shown to affect MACE.
CONCLUSIONS
In overall pooled analysis, both EMVO and LMVO
were associated with lower EF, larger ventricular
volumes and infarct at baseline, and worse adverse
LV remodeling at later time points after MI. LMVO
was demonstrated to have a stronger relationship
with MACE and the individual outcomes of cardiac
mortality, recurrent MI, and CHF/CHF hospitalization
compared with EMVO. IMH also predicted MACE;
however, there is a smaller body of literature for IMH
and limited direct comparisons of IMH and MVO. The
current literature is limited by the preponderance of
single-center studies using a variety of techniques
with imaging at different time points after infarction.
A multicenter study or registry with controlled
inclusion criteria, standardized methodology, and
timing relative to infarction is clearly needed to bet-
ter assess the independent impact of both MVO and
IMH on LV remodeling and MACE. Future advances in
CMR pulse sequences will enable improved quantiﬁ-
cation of the extent and severity of MVO and IMH.
CMR is well poised to study novel therapies to predict
and reduce ischemic reperfusion injury, and provides
a comprehensive multiparametric assessment of MI
including MVO and IMH.
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